Clinical Trial Update: A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects [Phase 2, Phase 3]

View source ↗

Summary

Pfizer conducted a 6-month dose-ranging study (Phase 2/Phase 3) to evaluate the weight loss effect of CP-945,598 in obese subjects. The trial status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 2, Phase 3 | Status: COMPLETED